Anxious depression and early changes in the HAMD-17 anxiety-somatization factor items and antidepressant treatment outcome

Amy H. Farabaugh, Stella Bitran, Janet Witte, Jonathan Alpert, Sarah Chuzi, Alisabet J. Clain, Lee Baer, Maurizio Fava, Patrick J. McGrath, Christina Dording, David Mischoulon, George I. Papakostas

Research output: Contribution to journalArticle

30 Scopus citations

Abstract

The objective of this study was to assess the relationship between early changes in anxiety/somatization symptoms and treatment outcome among major depressive disorder patients during a 12-week trial of fluoxetine. We also examined the relationship between anxious depression and treatment response. Five hundred and ten major depressive disorder patients received 12 weeks of fluoxetine with flexible dosing [target dosages: 10 mg/day (week 1), 20 mg/day (weeks 2-4), 40 mg/day (weeks 4-8), and 60 mg/day (weeks 5-12)]. We assessed the relationship between early changes in 17-item Hamilton Rating Scale for Depression (HAMD-17)-anxiety/somatization factor items and depressive remission, as well as whether anxious depression at baseline predicted remission at study endpoint. Baseline HAMD-17 scores were considered as covariates and the Bonferroni correction (P≤0.008) was used for multiple comparisons. Adjusting for baseline HAMD-17 scores, patients who experienced greater early improvement in somatic symptoms (gastrointestinal) were significantly more likely to attain remission (HAMD-17 <8) at endpoint than those without early improvement (P=0.006). Early changes in the remaining items did not predict remission, nor did anxious depression at baseline. In conclusion, among the anxiety/somatization factor items, only early changes in somatic symptoms (gastrointestinal) predicted remission. Future studies are warranted to further investigate this relationship as well as that between anxious depression and treatment outcome.

Original languageEnglish (US)
Pages (from-to)214-217
Number of pages4
JournalInternational Clinical Psychopharmacology
Volume25
Issue number4
DOIs
StatePublished - Jul 2010
Externally publishedYes

Keywords

  • Antidepressants
  • Anxiety
  • Anxious depression
  • Depression
  • Predictors
  • Remission

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Anxious depression and early changes in the HAMD-17 anxiety-somatization factor items and antidepressant treatment outcome'. Together they form a unique fingerprint.

  • Cite this

    Farabaugh, A. H., Bitran, S., Witte, J., Alpert, J., Chuzi, S., Clain, A. J., Baer, L., Fava, M., McGrath, P. J., Dording, C., Mischoulon, D., & Papakostas, G. I. (2010). Anxious depression and early changes in the HAMD-17 anxiety-somatization factor items and antidepressant treatment outcome. International Clinical Psychopharmacology, 25(4), 214-217. https://doi.org/10.1097/YIC.0b013e328339fbbd